Shareholder Loan

DCI Advisors Limited
06 October 2023
 

DCI Advisors Ltd

(the "Company" or "DCI")

Shareholder Loan

 

6 October 2023

 

The Board of the Company has entered into a further loan agreement for Euros 350,000 with a DCI shareholder to provide additional working capital to the Company.  When combined with the shareholder loans announced previously, all of the Shareholder Loans are expected to total up to €3.0 million in aggregate (the "Shareholder Loans" or "Shareholder Loan Agreements").  Four previous loans amounted to €350,000 each and two loans from funds managed by the same shareholder amounted to US$330,000 in aggregate. All of the previous Shareholder Loans have identical terms to one another (other than their date of initiation and currency of denomination) and are for a 12-month term bearing an interest rate of 12 per cent. p.a., with no fees payable on disbursement or repayment. The Company's intention is to repay the previous Shareholder Loans from the proceeds of the sale of Company assets. However, the new Shareholder Loan has identical terms except that there is no right of prepayment by the Company and it will therefore last 12 months. As the Shareholder Loans have not been repaid by 30 September 2023, collateral in the form of security over certain Company assets is being put in place using normal commercial terms which will exceed the aggregate value of each of the loans.

 

Enquiries

DCI Advisors Ltd

Nicolai Huls / Nick Paris, Managing Directors

 

nickparis@btinternet.com

+44 (0) 7738 470550

Cavendish Capital Markets (Nominated Adviser & Broker)

William Marle / Jonny Franklin-Adams / Edward Whiley / (Corporate Finance)

Pauline Tribe (Sales)

 

 

+44 (0) 20 7220 0500

FIM Capital Limited (Administrator)

Lesley Lennon / Grainne Devlin (Corporate Governance)

llennon@fim.co.im / gdevlin@fim.co.im

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings